公开(公告)号：US20230116770A1

公开(公告)日：2023-04-13

申请号：US17875216

申请日：2022-07-27

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Stephen GARDELL ,  Anthony B. PINKERTON ,  Eduard SERGIENKO ,  Hampton SESSIONS

IPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

摘要： Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230110216A1

公开(公告)日：2023-04-13

申请号：US17911429

申请日：2021-03-17

申请人： SINTETICA S.A.

发明人： Augusto Mitidieri ,  Elisabeta Donati ,  Clara Bianchi

IPC分类号： A61K31/245 ,  A61K9/06 ,  A61K47/38 ,  A61K9/00

摘要： Sterile ophthalmic gels of chloroprocaine having improved functionality, pharmacokinetics, and stability, particularly in terms of clarity, and to methods of making and using same.

公开(公告)号：US20230054250A1

公开(公告)日：2023-02-23

申请号：US17792499

申请日：2021-01-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Yong GAN ,  Shiyan GUO ,  Yinyin SUN

IPC分类号： A61K9/127 ,  A61K31/167 ,  A61K31/277 ,  A61K31/5415 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/138 ,  A61K31/475 ,  A61K31/4365 ,  A61K31/245 ,  A61K31/366 ,  A61K31/4422 ,  A61K47/10 ,  A61K47/24 ,  A61K47/14 ,  A61K47/44 ,  A61K47/28 ,  A61K9/00

摘要： A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

公开(公告)号：US20230036339A1

公开(公告)日：2023-02-02

申请号：US17760866

申请日：2020-09-17

申请人： The Queen's University of Belfast

发明人： Darren SVIRSKIS ,  Andrew HILL ,  Prabhat BHUSAL ,  Manisha SHARMA ,  Priyanka AGARWAL ,  Gavin ANDREWS ,  David JONES ,  Shu LI

IPC分类号： A61K47/32 ,  A61K31/167 ,  A61K31/192 ,  A61K31/245 ,  A61K31/445 ,  A61K9/70 ,  A61P23/02

摘要： The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

公开(公告)号：US20220378729A1

公开(公告)日：2022-12-01

申请号：US17755770

申请日：2020-11-05

申请人： SMARTECH TOPICAL, INC.

发明人： Thomas HNAT

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K47/12 ,  A61K47/10 ,  A61K47/38 ,  A61K47/20 ,  A61K31/192 ,  A61K31/167 ,  A61K31/405 ,  A61K31/60 ,  A61K31/7034 ,  A61K31/416 ,  A61K31/165 ,  A61K31/245

摘要： A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

公开(公告)号：US20220362217A1

公开(公告)日：2022-11-17

申请号：US17809339

申请日：2022-06-28

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/4162 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61P31/14 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US20220313707A1

公开(公告)日：2022-10-06

申请号：US17750888

申请日：2022-05-23

申请人： Suzhou Molecular Intersection Biomedical Co., Ltd.

发明人： Yifeng Zhou ,  Qiang Guo ,  Zheng Zhang ,  Binbin Guo ,  Siqi Wu

IPC分类号： A61K31/58 ,  A61K31/18 ,  A61K31/245 ,  A61K31/198 ,  A61K31/4166 ,  A61K31/4439 ,  A61K31/4155 ,  A61K31/5025 ,  A61P31/16 ,  A61P37/06

摘要： The present disclosure discloses use of a combination of an HIP-1α inhibitor and/or an AR inhibitor in inhibiting an .inflammatory cytokine storm,. treating or preventing viral pneumonia. The present disclosure finds that inhibitors HIF-1 a and AR prevent the transcription of inflammatory cytokine storm-related genes (IL6, MMP2, MMP13, ADAMTS4, ELN, VCAN. COL3A1 and VEGFA) in fibroblasts under low-oxygen environment by effectively inhibiting the interaction between HIF-1α and AR to reduce the expression quantity of the related genes, thereby influencing the activation of lung fibroblasts. Inhibition of activation of lung fibroblasts enables patients with acute respiratory distress syndrome (ARDS) due to severe respiratory tract infection to maintain the lung functions and improve clinical efficacy.

公开(公告)号：US11413350B2

公开(公告)日：2022-08-16

申请号：US17129715

申请日：2020-12-21

申请人： Heron Therapeutics, Inc.

发明人： Thomas B. Ottoboni ,  Lee Ann Lynn Girotti

IPC分类号： A61K47/34 ,  A61K31/5415 ,  A61K31/445 ,  A61K31/196 ,  A61K9/127 ,  A61K9/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/14 ,  A61K31/00 ,  A61K31/167 ,  A61K31/245 ,  A61K47/20 ,  A61K47/32

摘要： Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

公开(公告)号：US20220218740A1

公开(公告)日：2022-07-14

申请号：US17510383

申请日：2021-10-26

申请人： Vaporworks Nursing Anesthesia Inc.

发明人： Julia Harris

IPC分类号： A61K33/06 ,  A61K31/4164 ,  A61K31/167 ,  A61K31/245 ,  A61K31/135 ,  A61K31/573 ,  A61P25/36

摘要： Opioid-free compositions, methods and systems are described. The compositions comprise magnesium salt, an alpha-2 agonist, a sodium channel inhibitor, and optionally an NMDA antagonist, a beta-blocker, and/or a corticosteroid, together with a pharmaceutically acceptable vehicle, carrier, or excipient. The compositions are suitable for peri-operative and intra-operative methods for a patient undergoing a medical or surgical procedure.

公开(公告)号：US20220218648A1

公开(公告)日：2022-07-14

申请号：US17144471

申请日：2021-01-08

申请人： Banasthali Vidyapith

发明人： Sarvesh Paliwal ,  Swapnil Sharma ,  Neetika Tripathi ,  Kanika Verma ,  Swati Paliwal

IPC分类号： A61K31/245 ,  A61K9/20 ,  A61P9/12 ,  A61P3/06

摘要： The present invention relates to a method of using Mebeverine as an sEH inhibitor. The present invention also provides a method of treating metabolic and cardiovascular disorders using Mebeverine.